Literature DB >> 18381420

Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.

Shiyu Zhang1, Catherine M Phelan, Phil Zhang, Francois Rousseau, Parviz Ghadirian, Andre Robidoux, William Foulkes, Nancy Hamel, David McCready, Maureen Trudeau, Henry Lynch, Douglas Horsman, Maria Lourdes Leon De Matsuda, Zeba Aziz, Magda Gomes, Mauricio Magalhaes Costa, Alexander Liede, Aletta Poll, Ping Sun, Steven A Narod.   

Abstract

A founder allele in the CHEK2 gene (1100delC) has been associated with an elevated risk of breast cancer. This allele is responsible for the majority of CHEK2-associated breast cancers in women from northern European countries; however, within Europe, it seems to be rare in countries that are close to the Mediterranean. The frequency of the 1100delC allele has not been measured in non-White populations. We measured the frequency of the CHEK2 founder allele in 3,882 breast cancer patients and 8,609 controls from various countries. The allele was not seen among Asian patients (from Pakistan or the Philippines) and was present in 1 of 155 cases from Brazil. Among White women, the allele was present in 1.5% of 825 familial cases of breast cancer and in 0.7% of 1,106 patients with nonfamilial breast cancer. The allele was equally frequent in Jewish and non-Jewish patients. We estimate that the CHEK2 1100delC allele is associated with an odds ratio of 2.6 for breast cancer, which corresponds to a lifetime risk of approximately 24% in Ontario.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381420     DOI: 10.1158/0008-5472.CAN-07-5187

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer.

Authors:  Petra E A Huijts; Antoinette Hollestelle; Brunilda Balliu; Jeanine J Houwing-Duistermaat; Caro M Meijers; Jannet C Blom; Bahar Ozturk; Elly M M Krol-Warmerdam; Juul Wijnen; Els M J J Berns; John W M Martens; Caroline Seynaeve; Lambertus A Kiemeney; Henricus F van der Heijden; Rob A E M Tollenaar; Peter Devilee; Christi J van Asperen
Journal:  Eur J Hum Genet       Date:  2013-05-08       Impact factor: 4.246

Review 2.  Breast cancer in young women.

Authors:  Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2012-06-26       Impact factor: 66.675

3.  Variant allele of CHEK2 is associated with a decreased risk of esophageal cancer lymph node metastasis in a Chinese population.

Authors:  Haiyong Gu; Wanshan Qiu; Ying Wan; Guowen Ding; Weifeng Tang; Chao Liu; Yijun Shi; Yijang Chen; Suocheng Chen
Journal:  Mol Biol Rep       Date:  2011-12-27       Impact factor: 2.316

Review 4.  Phenotype-genotype correlation in familial breast cancer.

Authors:  Ana Cristina Vargas; Jorge S Reis-Filho; Sunil R Lakhani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-12       Impact factor: 2.673

5.  Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.

Authors:  Aglaya G Iyevleva; Svetlana N Aleksakhina; Anna P Sokolenko; Sofia V Baskina; Aigul R Venina; Elena I Anisimova; Ilya V Bizin; Alexandr O Ivantsov; Yana V Belysheva; Alexandra P Chernyakova; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Breast Cancer Res Treat       Date:  2022-01-12       Impact factor: 4.872

6.  The CHEK2*1100delC Mutation and Adolescent Breast Cancer: A Case Report of Breast Cancer in a 19-Year-Old and a Review of the Literature.

Authors:  Tahereh Soleimani; Abigail J Engwall; Corrie Bourdon; Mohammad A Torabi; Thais Fortes
Journal:  Breast Care (Basel)       Date:  2021-03-08       Impact factor: 2.860

7.  CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.

Authors:  Eswary Thirthagiri; Leng San Cheong; Cheng Har Yip; Soo-Hwang Teo
Journal:  Fam Cancer       Date:  2009-04-28       Impact factor: 2.375

Review 8.  Bilateral breast cancers.

Authors:  Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2014-02-04       Impact factor: 66.675

9.  Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility.

Authors:  Irene Catucci; Ana Osorio; Brita Arver; Guido Neidhardt; Massimo Bogliolo; Federica Zanardi; Mirko Riboni; Simone Minardi; Roser Pujol; Jacopo Azzollini; Bernard Peissel; Siranoush Manoukian; Giovanna De Vecchi; Stefano Casola; Jan Hauke; Lisa Richters; Kerstin Rhiem; Rita K Schmutzler; Karin Wallander; Therese Törngren; Åke Borg; Paolo Radice; Jordi Surrallés; Eric Hahnen; Hans Ehrencrona; Anders Kvist; Javier Benitez; Paolo Peterlongo
Journal:  Genet Med       Date:  2017-08-24       Impact factor: 8.822

10.  Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.

Authors:  Marjanka K Schmidt; Frans Hogervorst; Richard van Hien; Sten Cornelissen; Annegien Broeks; Muriel A Adank; Hanne Meijers; Quinten Waisfisz; Antoinette Hollestelle; Mieke Schutte; Ans van den Ouweland; Maartje Hooning; Irene L Andrulis; Hoda Anton-Culver; Natalia N Antonenkova; Antonis C Antoniou; Volker Arndt; Marina Bermisheva; Natalia V Bogdanova; Manjeet K Bolla; Hiltrud Brauch; Hermann Brenner; Thomas Brüning; Barbara Burwinkel; Jenny Chang-Claude; Georgia Chenevix-Trench; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Alison M Dunning; Peter A Fasching; Jonine Figueroa; Olivia Fletcher; Henrik Flyger; Eva Galle; Montserrat García-Closas; Graham G Giles; Lothar Haeberle; Per Hall; Peter Hillemanns; John L Hopper; Anna Jakubowska; Esther M John; Michael Jones; Elza Khusnutdinova; Julia A Knight; Veli-Matti Kosma; Vessela Kristensen; Andrew Lee; Annika Lindblom; Jan Lubinski; Arto Mannermaa; Sara Margolin; Alfons Meindl; Roger L Milne; Taru A Muranen; Polly A Newcomb; Kenneth Offit; Tjoung-Won Park-Simon; Julian Peto; Paul D P Pharoah; Mark Robson; Anja Rudolph; Elinor J Sawyer; Rita K Schmutzler; Caroline Seynaeve; Julie Soens; Melissa C Southey; Amanda B Spurdle; Harald Surowy; Anthony Swerdlow; Rob A E M Tollenaar; Ian Tomlinson; Amy Trentham-Dietz; Celine Vachon; Qin Wang; Alice S Whittemore; Argyrios Ziogas; Lizet van der Kolk; Heli Nevanlinna; Thilo Dörk; Stig Bojesen; Douglas F Easton
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.